About Us
Company Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Contact Us
Our Approach
The Opportunity in China
The Everest Advantage
Partners
Pipeline
Media
Investors
News
Search
06
2021/05
Everest Medicines Receives Orphan Drug Designation from the Ministry of Food and Drug Safety in South Korea for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
15
2021/04
Everest Medicines Appoints Jennifer Yang as Chief Scientific Officer
14
2021/04
Everest Medicines Announces that the US FDA has Granted Licensing Partner Gilead Sciences, Inc. Accelerated Approval of Trodelvy
®
for the Treatment of Metastatic Urothelial Cancer
09
2021/04
Everest Medicines Announces that Licensing Partner Gilead Sciences, Inc. has Received Full US FDA Approval of Trodelvy
®
for the Treatment of Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
31
2021/03
Everest Medicines Announces China NMPA Approval of Clinical Trial Application to Evaluate Trodelvy
®
in a Phase 2 Basket Trial for a Variety of Cancers with High TROP-2 Expression
22
2021/03
Everest Medicines Announces Acceptance of New Drug Application by China NMPA for Xerava
™
for the Treatment of Complicated Intra-abdominal Infections
22
2021/03
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2020
19
2021/03
Everest Medicines to Announce Full-Year 2020 Financial Results on March 22, 2021
01
2021/03
Everest Medicines Announces Selection as a Constituent of Certain Indexes of Hang Seng Indexes Company Limited
18
2021/02
Everest Medicines Appoints Kevin Guo as Chief Commercial Officer
21
2021/01
Everest Medicines CEO Awarded the 13th Health China Top 10 Pharmaceutical Business Leaders Award
18
2021/01
Everest Medicines Announces Amended Agreement with Spero Therapeutics
<<
<
1
2
3
4
5
6
7
8
9
10
>
>>
Copyright Everest Medicines 2020 云顶药业(苏州)有限公司
苏ICP备20038571号
|
Terms of Use
|
Privacy Policy
|
Disclaimers
沪公网安备 31010602006477号
a>